Free Trial

Nyxoah Q2 2023 Earnings Report

Nyxoah logo
$6.08 -0.91 (-13.02%)
As of 04:00 PM Eastern

Nyxoah EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.45
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
$1.21 million
Expected Revenue
$1.04 million
Beat/Miss
Beat by +$170.00 thousand
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Nyxoah Earnings Headlines

Your Retirement Is Caught in the Crossfire
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
Kepler Capital Remains a Buy on Nyxoah (NYXH)
HC Wainwright Has Positive Outlook for Nyxoah Q1 Earnings
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

View Nyxoah Profile

More Earnings Resources from MarketBeat